Quick Answer
CRISPR Therapeutics AG reported Revenue (ASC 606) of $3.51 million for fiscal year 2025.
CRISPR Therapeutics AG Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $3.51M | -90.6% |
| 2024 | $37.31M | -89.9% |
| 2023 | $371.21M | +30885.5% |
| 2022 | $1.20M | -99.9% |
| 2021 | $914.96M | +127154.9% |
| 2020 | $719.0K | -99.8% |
| 2019 | $289.59M | +9169.8% |
| 2018 | $3.12M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $889.0K | +47.7% | -0.3% |
| June 30, 2025 | $892.0K | +72.5% | +3.1% |
| March 31, 2025 | $865.0K | +71.6% | +43.7% |
| September 30, 2024 | $602.0K | — | +16.4% |
| June 30, 2024 | $517.0K | -99.3% | +2.6% |
| March 31, 2024 | $504.0K | -99.5% | — |
| September 30, 2023 | $0.00 | -100.0% | -100.0% |
| June 30, 2023 | $70.00M | +44203.8% | -30.0% |
- CRISPR Therapeutics AG showed a decrease of -90.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2018–2025 period, CRISPR Therapeutics AG’s revenue (asc 606) has grown by 12.4% (from $3.12 million to $3.51 million).
- The most recent figure is from CRISPR Therapeutics AG’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: